These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 21247382)

  • 1. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
    Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
    Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
    Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
    Raninga PV; Lee A; Sinha D; Dong LF; Datta KK; Lu X; Kalita-de Croft P; Dutt M; Hill M; Pouliot N; Gowda H; Kalimutho M; Neuzil J; Khanna KK
    Theranostics; 2020; 10(12):5259-5275. PubMed ID: 32373211
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
    Chauhan D; Hideshima T; Anderson KC
    Br J Cancer; 2006 Oct; 95(8):961-5. PubMed ID: 17047643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marizomib, a potent second generation proteasome inhibitor from natural origin.
    Ma L; Diao A
    Anticancer Agents Med Chem; 2015; 15(3):298-306. PubMed ID: 25403165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New proteasome inhibitors in myeloma.
    Lawasut P; Chauhan D; Laubach J; Hayes C; Fabre C; Maglio M; Mitsiades C; Hideshima T; Anderson KC; Richardson PG
    Curr Hematol Malig Rep; 2012 Dec; 7(4):258-66. PubMed ID: 23065395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
    Singh AV; Palladino MA; Lloyd GK; Potts BC; Chauhan D; Anderson KC
    Br J Haematol; 2010 May; 149(4):550-9. PubMed ID: 20331453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor therapy in multiple myeloma.
    Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
    Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
    Kuhn DJ; Orlowski RZ; Bjorklund CC
    Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the proteasome pathway.
    Tsukamoto S; Yokosawa H
    Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of proteasome inhibitors in cancer therapy.
    Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
    Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.